Gamida Cell and Cellerixon collaborate to develop new line of cell therapeutics

Gamida Cell Ltd. and Cellerix, S.A. announced today that the companies are collaborating on a feasibility study to evaluate the added value of combining the proprietary technologies of each.

Gamida Cell is developing a series of technologies to expand, ex vivo, populations of stem/progenitor cells that display increased in vivo homing and engraftment activities. The company's lead product, StemEx(R), comprised of expanded populations of adult stem cells derived from umbilical cord blood (UCB), is used today as an experimental treatment for blood cancers like leukemia and lymphoma. The Company anticipates StemEx(R) will reach the market in 2011.

Cellerix is developing a new generation of cell-based medicines using expanded adult stem cells (eASCs) obtained from adipose tissue. The Company is also very active developing its allogeneic eASCs platform as 2nd generation products through its Cx611 program for high potential markets. eASCs are a natural medicine with the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a potential revolution in the treatment of some diseases that cannot satisfactorily be cured at present.

"Gamida Cell is enthusiastic about working with Cellerix, a world class company and an industry leader," said Dr. Yael Margolin, president and CEO of Gamida Cell. "Gamida Cell's technologies have demonstrated to improve in vivo functionality of ex-vivo expanded hematopoietic stem cells. This collaboration seeks to evaluate the feasibility of improving clinical efficacy of ex vivo expanded adult stem cells obtained from adipose tissue by means of increasing homing and retention following infusion. The results of this study could lead to an entirely new understanding of the widespread application of our various technologies and expand the number of possibilities for Gamida Cell in terms of product development and partnerships."

"Cellerix has a promising pipeline of cell therapeutics in advanced clinical trials. Existing data shows that Gamida Cell's expansion technologies are very effective in hematopoietic stem cells. Combining the technologies of our companies could lead to developing a new line of cell therapeutics. We are looking forward to seeing the results of this collaboration with an eye on further co-development and commercialization opportunities," said Eduardo Bravo, CEO at Cellerix.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Vaccine-induced immune responses for SARS-CoV-2 in patients receiving anti-CD20 B-cell depleting therapies